- Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of SPY001, its Novel Half-life Extended anti-α4β7 Antibody, for the Treatment of Inflammatory Bowel Disease
- Spyre Therapeutics Announces Grants of Inducement Awards
- Spyre Therapeutics to Participate in the Jefferies Global Healthcare Conference
- Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors
- Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
More ▼
Key statistics
On Friday, Spyre Therapeutics Inc (SYRE:NSQ) closed at 31.47, -34.40% below its 52-week high of 47.97, set on Mar 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 30.84 |
---|---|
High | 31.54 |
Low | 30.24 |
Bid | 31.10 |
Offer | 33.11 |
Previous close | 30.11 |
Average volume | 431.22k |
---|---|
Shares outstanding | 50.78m |
Free float | 46.23m |
P/E (TTM) | -- |
Market cap | 1.60bn USD |
EPS (TTM) | -71.35 USD |
Data delayed at least 15 minutes, as of Jul 26 2024 21:00 BST.
More ▼